

36. The construct of claim 30, wherein said at least one other arm that specifically binds a targetable conjugate is a monoclonal antibody or a fragment of a monoclonal antibody.

~~37. The construct of claim 30, wherein said at least one arm that specifically binds a targeted tissue is a humanized antibody or a fragment of a humanized antibody.~~

38. The construct of claim 30, wherein said at least one other arm that specifically binds a targetable conjugate is a humanized antibody or a fragment of a humanized antibody.

~~39. The construct of claim 30, wherein said at least one other arm specifically binds peptide.~~

40. The construct of claim 30, wherein said at least one other arm specifically binds a carbohydrate.

41. The construct of claim 30, wherein said at least one other arm specifically binds a hapten.

42. The construct of claim 30, wherein said at least one other arm specifically binds a chelator or a metal-chelate complex.

43. The construct of claim 42, wherein said chelator is a hard base chelator for a hard acid cation.

~~44. The construct of claim 42, wherein said chelator is a soft base chelator for a soft acid cation.~~

45. The construct of claim 43, wherein said chelator is a hard base chelator that comprises carboxylate and amine groups.

sub 32
46. The construct of claim 43, wherein said hard base chelator is DTPA, NOTA, DOTA or TETA.

sub 317
~~47. The construct of claim 30, wherein said at least one other arm specifically binds a tyrosyl-lysine dipeptide.~~

48. The construct of claim 30, wherein said at least one other arm specifically binds Tyr-Lys(DTPA)-NH₂, or Lys(DTPA)-Tyr-Lys(DTPA)-NH₂.

A' could
49. The set of expression cassettes of claim 31, wherein a first expression cassette is capable of producing in a host cell a fragment of a bi-specific fusion protein and comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a scFv linked to a Fd fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said fragment of said bi-specific fusion protein is under the control of said regulatory regions.

sub 318
~~50. The set of expression cassettes of claim 49, wherein a second expression cassette is capable of producing in a host cell a light-chain antibody fragment which is complementary to said Fd fragment in and comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a light-chain antibody fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said light-chain antibody fragment is under the control of said regulatory regions, and wherein said light-chain antibody fragment, when associated with said Fd fragment, forms a Fab fragment whose binding site is specific for said targeted tissue.~~